Drugs / BIIL 283 BS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00060801 | May 2003 → Jul 2004 | cystic fibrosis | Boehringer Ingelheim | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIL 283 BS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00060801 ↗ |
| Known as | Amelubent | “BIIL 283 BS (Amelubent)” NCT00060801 ↗ |
| Route | Oral | “24 Weeks of Oral Treatment” NCT00060801 ↗ |